Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Ditropan XL Patent Invalidated In Mylan Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan win evens score before W.Va. District Court judge who had previously ruled J&J's Levaquin patents were valid and infringed.

You may also be interested in...



Mylan And J&J Cut A Deal For Generic Ditropan XL

Mylan could become the authorized generic for the 15 mg dose of the overactive bladder product.

Mylan And J&J Cut A Deal For Generic Ditropan XL

Mylan could become the authorized generic for the 15 mg dose of the overactive bladder product.

Mylan Loses Challenge To “Authorized” Generics In W.Va. Court

Federal judge says 180-day exclusivity period was not intended to prohibit competition from NDA holder.

Related Content

Topics

UsernamePublicRestriction

Register

PS062962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel